Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator-Comparison of Five European Healthcare Systems.

Journal of Diabetes Science and Technology
Katharina FritzenOliver Schnell

Abstract

Costs for the treatment of diabetes and its comorbidities are a major international issue. A recent randomized clinical trial showed that the introduction of color range indicator (CRI)-based glucose meters (GMs) positively affects the HbA1c of patients with type 1 and type 2 diabetes, when compared to GMs without a CRI. This budget impact analysis aimed to translate this beneficial effect of CRI-based GMs, OneTouch Verio Flex and OneTouch Verio, into potential monetary impact for the healthcare systems of five European countries, Germany, Spain, Italy, France, and the United Kingdom. Data from a randomized controlled trial, evaluating the effect of CRI-based GMs, were used to estimate the ten-year risk of patients for fatal myocardial infarction (MI) as calculated by the UK Prospective Diabetes Study (UKPDS) risk engine. On the basis of assessed risks for MI, the potential monetary impact for the healthcare systems in five European countries was modeled. Based on a mean HbA1c reduction of 0.36%, as demonstrated in a randomized controlled trial, the UKPDS risk engine estimated a reduction of 2.4% of the ten-year risk of patients for fatal MI. When applied to our economic model, substantial potential cost savings for the healthc...Continue Reading

References

Feb 10, 2007·Diabetes Care·Angelo AvogaroUNKNOWN Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità
Dec 17, 2009·Diabetes Technology & Therapeutics·Nalinee PoolsupSomying Rattanasookchit
Oct 6, 2010·Journal of Diabetes Science and Technology·Mark Uslan, Morgan Blubaugh
Jan 26, 2011·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·I KösterI Schubert
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Jan 10, 2012·Journal of Diabetes Science and Technology·David C KlonoffUNKNOWN Coalition for Clinical Research-Self-Monitoring of Blood Glucose Scientific Board
Oct 16, 2012·Journal of General Internal Medicine·Fatima Al SayahJeffrey A Johnson
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Aug 6, 2013·Journal of Diabetes Science and Technology·Oliver SchnellEva Wintergerst
Jan 21, 2014·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Francisco ArrietaUNKNOWN Study Group on Diabetes
May 31, 2014·Journal of Diabetes Science and Technology·Oliver Schnell, Michael Erbach
Dec 3, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·M L AlvaR R Holman
Nov 3, 2016·Journal of Diabetes Science and Technology·Marc C Torjman
Apr 27, 2017·Journal of Diabetes Science and Technology·Oliver SchnellMichael Hummel
Oct 24, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·S A MostafaM A Bethel
Feb 25, 2018·Diabetes Care·Christian BommerSebastian Vollmer
Apr 24, 2018·Journal of Diabetes Science and Technology·Robert Brett McQueenJonathan D Campbell

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Flex
OneTouch Verio
Verio
OneTouch Verio Flex

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.